ADC Therapeutics SA Cash on Hand 2019-2022 | ADCT

ADC Therapeutics SA cash on hand from 2019 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
ADC Therapeutics SA Annual Cash on Hand
(Millions of US $)
2021 $467
2020 $439
2019 $116
2018 $139
ADC Therapeutics SA Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $431
2021-12-31 $467
2021-09-30 $530
2021-06-30 $372
2021-03-31 $383
2020-12-31 $439
2020-09-30 $494
2020-06-30 $349
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2018-12-31 $139
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.034B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00